
The Baldwin Group: Companies May Be Over-Insuring Directors & Officers (D&O) Coverage by Millions, Study with Nasdaq Finds
'This year's data still shows rates are coming down at renewal, however, we still believe most companies aren't deploying their capital strategically,' said Michael Tomasulo, Senior Managing Partner & National Practice Leader at The Baldwin Group.
Share
According to the findings, average premium costs and retentions continued to decline in 2024, extending a three-year trend of softening market conditions. Yet, the findings also raise new questions about whether companies are over-insuring relative to their true litigation exposure, potentially leaving meaningful cost savings on the table.
Average retention levels dropped from $2.5 million to $1.5 million, and the average premium for $5 million in limits fell to $277,985, down from $315,222 last year. Technology and healthcare led all sectors in rate reductions at –15.0% and –13.6%, respectively. However, benchmarking data suggests many companies, especially mid-cap firms, are still buying far more insurance than they need.
'This year's data, like the past few years, still shows rates are coming down at renewal, however, we still believe most companies aren't deploying their capital strategically,' said Michael Tomasulo, Senior Managing Partner & National Practice Leader at The Baldwin Group. 'Our data shows that while a company may be purchasing $40 million in D&O limits, their actual claims exposure might be a fraction of that – essentially purchasing limits they may never actually need.'
According to data drawn from Stanford Securities Litigation Analytics and The Baldwin Group's own benchmarking, a public company with a market cap of $500 million to $1 billion faces an average settlement of $8.2 million in a securities class action, with total risk exposure (after legal costs and other factors) ranging from $12 million to $15 million. Yet many companies in this cohort are purchasing up to $40 million in coverage, signaling a potential over-insurance gap of $15 to $20 million.
'Too often, insurance decisions get treated as one-off transactions. At Baldwin, we take a different approach—advising companies on the smartest path forward based on their actual risk exposure, business goals, and capital priorities,' said Dan Galbraith, President, The Baldwin Group and CEO, Retail Brokerage Operations. 'This report gives leaders the clarity to right-size their D&O programs—not just to save money, but to ensure that every dollar spent supports the bigger picture of how they grow, govern, and protect their business.'
The report also provides granular benchmarking for premium changes by sector and market capitalization size, enabling companies to compare their renewal experience against similar peers. While the market continues to soften with the overall average rate change in 2024 at -9.7%, the report emphasizes that premium savings mean little if programs remain misaligned with actual exposure.
For more details or to request access to the full report, visit www.baldwin.com.
ABOUT THE 2025 D&O BENCHMARKING REPORT
Produced in collaboration with Nasdaq, The Baldwin Group's D&O Benchmarking Report provides a data-driven overview of public company D&O program structures by industry and market capitalization. Findings are drawn from more than 250 companies and offer unique insight into the alignment between purchased insurance limits and real-world claim activity. Please note that this report should be used as a guide and does not constitute individualized financial advice. The full report is available to companies that completed the benchmarking survey.
ABOUT THE BALDWIN GROUP
The Baldwin Group, the brand name for The Baldwin Insurance Group, Inc. (NASDAQ: BWIN) and its affiliates, is an independent insurance distribution firm providing indispensable expertise and insights that strive to give our clients the confidence to pursue their purpose, passion, and dreams. As a team of dedicated entrepreneurs and insurance professionals, we have come together to help protect the possible for our clients. We do this by delivering bespoke client solutions, services, and innovation through our comprehensive and tailored approach to risk management, insurance, and employee benefits. We support our clients, colleagues, insurance company partners, and communities through the deployment of vanguard resources and capital to drive our organic and inorganic growth. The Baldwin Group proudly represents more than three million clients across the United States and internationally. For more information, please visit www.baldwin.com.
This press release may contain various 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, which represent Baldwin's expectations or beliefs concerning future events. Forward-looking statements are statements other than historical facts and may include statements that address Baldwin's future operating, financial or business performance or Baldwin's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as 'may,' 'might,' 'will,' 'should,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'predicts,' 'projects,' 'potential,' 'outlook' or 'continue,' or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. Factors that could cause actual results or performance to differ from the expectations expressed or implied in such forward-looking statements include, but are not limited to, those described under the caption 'Risk Factors' in Baldwin's Annual Report on Form 10-K for the year ended December 31, 2024 and in Baldwin's other filings with the U.S. Securities and Exchange Commission (the 'SEC'), which are available free of charge on the SEC's website at: www.sec.gov, including those risks and other factors relevant to Baldwin's business, financial condition and results of operations. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Baldwin or to persons acting on Baldwin's behalf are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Baldwin does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Wells Fargo Upgrades Cintas (CTAS) Stock to Equal Weight, Raises PT
Cintas Corporation (NASDAQ:CTAS) is one of the Top 10 Transportation and Industrial Stocks to Buy Now. Wells Fargo upgraded the company's stock to 'Equal Weight' from 'Underweight' with a price objective of $221, up from the prior target of $196, as reported by The Fly. The upgrade demonstrates the firm's expectation of Cintas Corporation (NASDAQ:CTAS) achieving greater market share gains from competitors. Furthermore, the firm cited the company's superior infrastructure, less unionized workforce, healthier balance sheet, and more tenured management team as critical advantages in the broader competitive environment. A corporate office with staff members wearing company branded uniforms. Overall, the firm highlighted that Cintas Corporation (NASDAQ:CTAS) managed to weather the tough macroeconomic environment better than its peers, and the firm believes that there is an attractive opportunity for Cintas Corporation (NASDAQ:CTAS) to enhance its share gains. In Q3 2025, the company's revenue came in at $2.61 billion as compared to $2.41 billion in last year's third quarter, reflecting 8.4% growth. This was positively impacted by 0.9% because of acquisitions and negatively impacted by 0.4% as a result of foreign currency exchange rate fluctuations. Cintas Corporation (NASDAQ:CTAS) updated its annual revenue expectations from the range of $10.255 billion – $10.320 billion to $10.280 billion – $10.305 billion. Cintas Corporation (NASDAQ:CTAS) is engaged in renting and servicing uniforms and other garments, such as flame-resistant clothing, mats, mops, and shop towels, as well as other ancillary items. It offers its products and services via the distribution network and local delivery routes, or local representatives to small service and manufacturing companies, and well-established corporations. The company's offerings make it a backbone provider for the broader operational infrastructure, which is critical to the industrial services sector. While we acknowledge the potential of CTAS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. 登入存取你的投資組合
Yahoo
29 minutes ago
- Yahoo
UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) is one of the 11 best debt-free stocks to invest in right now. The company boasts a strong portfolio led by Tyvaso, its inhaled therapy for pulmonary hypertension, and a growing pipeline targeting pulmonary arterial hypertension (PAH). Its existing therapies are leading to stronger topline and earnings growth; the 17% year-over-year growth in Q1 2025 revenue and a 17% compounded annual growth rate (CAGR) over the last five years are evidence of that. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. UBS analyst Ashwani Verma maintained a Buy rating on United Therapeutics (NASDAQ:UTHR) on June 30 but adjusted the price target to $385 from $410, reflecting a recalibration of expectations ahead of a key clinical update. Verma pointed to the company's upcoming Phase III readout for idiopathic pulmonary fibrosis (IPF), expected in the third quarter, as a potential high-impact event that could meaningfully influence the stock. While binary in nature, the analyst believes the risk/reward remains attractive at current valuation levels. Verma also highlighted Tyvaso as a continued bright spot for the company. He expects the therapy to see seasonally strong performance in both Q2 and Q3, which should support near-term revenue momentum. While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company secured accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) on July 2, 2025, marking a significant progress in the treatment of relapsed or refractory multiple myeloma in patients who have undergone four or more prior therapies. The approval adds depth to the company's late-stage pipeline. Moreover, it enhances the company's long-term growth trajectory in a high-need, underserved segment of the cancer market. A medical professional holding vials of biotechnology therapeutic candidate. On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 price target. Although Regeneron has faced recent headwinds, particularly around Eylea, Schott expects those pressures to ease. He points to patient affordability issues and competitive dynamics as near-term hurdles, but believes the enhanced Eylea HD formulation and expanded copay assistance programs should help stabilize sales. Offsetting some of this softness is the continued strength of Dupixent, which Schott sees as a key growth engine, especially as new indications expand its market reach. Looking ahead, Schott views the setup for Regeneron shares as compelling. With a strong balance sheet and growing contributions from Dupixent, he sees room for upside even without relying on near-term pipeline catalysts. However, potential updates, including LAG-3 data in melanoma and further clarity on Eylea, could serve as meaningful valuation drivers. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is a biotechnology company focused on discovering, developing, and distributing innovative therapies that address serious and life-threatening diseases. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data